Peer-influenced content. Sources you trust. No registration required. This is HCN.
News Medical
A case report describes successful kidney transplantation in a highly sensitized patient whose probability of finding a compatible donor had been considered effectively zero. Treatment with teclistamab substantially reduced anti-HLA antibodies, enabling transplantation after prolonged wait-list status.
Hematology/Oncology August 17th 2026
The American Journal of Respiratory and Critical Care Medicine (AJRCCM)
The American Thoracic Society updated guidance for childhood interstitial lung disease in infants, emphasizing genetic testing, chest imaging, biopsy indications, and transplant referral. Recommendations formalize evaluation priorities for rare pediatric lung disorders.
Medical Genetics August 13th 2026
Clinical Infectious Diseases (CID)
A retrospective quasi-experimental study at St. Jude Children’s Research Hospital found that discontinuing empiric antibiotics within 72 hours of febrile neutropenia onset in clinically stable pediatric haploidentical HCT recipients reduced antibiotic exposure by a median of 8 days without significant differences in bloodstream infection, ICU admission, or mortality.
Pediatric Hematology/Oncology June 17th 2026
Hematology Advisor
To help patients and clinicians in strategizing about care decisions at the individual level, ASH convened a multidisciplinary panel — which included experts and patient representatives — to form standardized guidelines for newly diagnosed AML in older patients.
Hematology/Oncology March 30th 2026
Cardiology Advisor
Continued collaboration across disciplines, enhanced focus on standardization, and investments in emerging technologies are imperative for bridging the gaps and driving innovation.
Cardiology February 10th 2026
Oncology News Central (ONC)
“We are surprised and disappointed by this FDA decision for EBV+ PTLD patients who have a significant unmet need, highlighted by tabelecleucel’s orphan drug designation and by the granting of breakthrough status.” — Dr. Cokey Nguyen, Atara CEO
Hematology/Oncology January 20th 2026